Tumor response assessment in patients by ICR across analyses from Study 15401-3

Response rates in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation1


Tumor response assessment in patients by ICR across analysis from clinical study 1540

  • CI=confidence interval; CR=complete response; CSCC=cutaneous squamous cell carcinoma; ICR=independent central review; laCSCC=locally advanced CSCC; mCSCC=metastatic CSCC; ORR=objective response rate; PR=partial response; Q2W=every 2 weeks; Q3W=every 3 weeks.

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1


References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program; May 29-31, 2020.